| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | 10-Q |
| 13 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 05 Nov 2026 |
Form 4: Moorhead John Hunnewell Jr, Director
Granted 1,760 Stock Option (Right to Buy) |
| 05 Nov 2026 |
Form 3: Moorhead John Hunnewell Jr, Director
No securities owned |
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
ATLANTA – October 30, 2026 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and ... |
| 15 Oct 2026 | SCHEDULE 13G |
| 29 Sep 2026 | 424B3 |
| 28 Sep 2026 | EFFECT |
| 03 Sep 2026 | S-3 |
| 31 Aug 2026 | SCHEDULE 13G |
| 20 Aug 2026 | D |
| 17 Aug 2026 | SCHEDULE 13D |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval -- |
| 14 Aug 2026 | SCHEDULE 13G |
| 11 Aug 2026 |
Form 4: Eichenbaum Kenneth D., Director
Granted 880 Stock Option (Right to Buy) |
| 11 Aug 2026 |
Form 4: Uzialko Edward R, Director
Granted 880 Stock Option (Right to Buy) |
| 11 Aug 2026 |
Form 4: Milnes Alistair, Director
Granted 880 Stock Option (Right to Buy) |
Loading...